



Research on Ocular and Intraocular Tumors

Guest Editors:

Dr. Lothar Krause

Department of Ophthalmology,
Dessau Hospital, Brandenburg
Medical School Theodor
Fontane, Auenweg 38, 06847
Dessau, Germany

Dr. Ilja Frank Ciernik

Departments of Radiation
Oncology, Dessau Hospital,
Brandenburg Medical School
Theodor Fontane, Auenweg 38,
06847 Dessau, Germany

Deadline for manuscript
submissions:

closed (15 August 2023)

Message from the Guest Editors

Tumors of the eye are classified as orbital or intraocular neoplasia. Orbital diseases include lymphoma and metastasis. Primary orbital tumors are rare, such as conjunctival melanoma, and are often difficult to treat, with high rates of recurrence and metastasis.

Choroidal melanoma has the highest prevalence of all primary intraocular tumors. Primary disease control and eye preservation are achieved in most patients, because effective and complementary treatment strategies, ascertaining to local tumor control, exist. Classically, brachytherapy with iodine or ruthenium plaques, proton therapy, or radiosurgery with photons are commonly being employed. Metastatic spread, however, has remained challenging and therapeutic options remain limited, although important progress has been made with immunotherapies in recent years.

The current Special Issue of *Cancers* is set to highlight novel developments in translational medicine, organ-preserving therapies for intraocular tumors, and innovative strategies regarding how to most appropriately deal with metastatic disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)